Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Oligodendroglioma Stories

2012-01-27 10:30:36

Researchers at UT Southwestern Medical Center have developed what they believe to be the first clinical application of a new imaging technique to diagnose brain tumors. The unique test could preclude the need for surgery in patients whose tumors are located in areas of the brain too dangerous to biopsy. This new magnetic resonance spectroscopy (MRS) technique provides a definitive diagnosis of cancer based on imaging of a protein associated with a mutated gene found in 80 percent of low-...

2012-01-24 11:50:37

UCSF Team Develops Methods That May Help Predict Tumor Progression and Improve Treatment Follow-up After people with low-grade glioma, a type of brain cancer, undergo neurosurgery to remove the tumors, they face variable odds of survival – depending largely on how rapidly the cancer recurs. Even though their doctors monitor the tumor closely with sophisticated imaging, it is difficult to determine with certainty whether cancer has returned in a more malignant state that requires...

2012-01-19 20:42:22

A recent analysis of clinical trial results performed by the Radiation Therapy Oncology Group (RTOG) demonstrate that a chromosomal abnormality–specifically, the absence (co-deletion) of chromosomes 1p and 19q–have definitive prognostic and predictive value for managing the treatment of adult patients with pure and mixed anaplastic oligodendrogliomas. The presence of the chromosomal abnormality was associated with a substantially better prognosis and near-doubling of median...

2011-12-12 22:23:28

Glioblastoma multiforme (GBM) is the most common and lethal of all human brain tumors that originate in the brain. For most patients, treatment involves surgery followed by both radiation therapy and chemotherapy with temozolomide. However, many GBMs are resistant to the effects of temozolomide. A team of researchers led by Sameer Agnihotri, at the University of Toronto, Toronto, has now determined that the protein APNG can contribute to GBM resistance to the effects of temozolomide....

2011-12-02 08:00:00

PORTSMOUTH, N.H., Dec. 2, 2011 /PRNewswire/ -- Novocure(TM), a commercial stage private oncology company, has announced that prominent neuro-oncologists at four clinical centers in the U.S. will be the first to provide access to its Tumor Treating Fields (TTFields)(TM) device, NovoTTF-100A System(TM), for the treatment of recurrent glioblastoma multiforme (GBM). GBM is a deadly brain tumor affecting approximately 10,000 Americans each year. The NovoTTF(TM) device, approved by...

2011-11-21 08:00:00

ANAHEIM, Calif., Nov. 21, 2011 /PRNewswire/ -- Novocure(TM), a commercial stage private oncology company, announced today that Dr. Eric T. Wong, Co-Director, Brain Tumor Center, Beth Israel Deaconess Medical Center in Boston, presented follow-up results of a study focusing on overall survival in patients with recurrent glioblastoma multiforme (GBM). The long-term follow-up results from the Phase III EF-11 study compared overall survival at two and three years after initiating therapy in...

2011-09-29 09:20:45

Brain tumor specimens taken from neurosurgery cases at the University of California, San Francisco (UCSF) Medical Center has given scientists a new window on the transformation that occurs as healthy brain cells begin to form tumors. The work may help identify new drugs to target oligodendroglioma, a common type of brain tumor, at its earliest stage, when it is generally most treatable. Any potential drugs identified will have to prove safe and effective in clinical trials, a process that...

2011-09-20 00:13:36

Study led by St. Jude Children´s Research Hospital scientists points to possible new treatment targets for diffuse intrinsic pontine gliomas; may tip the scales in the current debate about tumor biopsies The largest study ever of a rare childhood brain tumor found more than half the tumors carried extra copies of specific genes linked to cancer growth, according to research led by St. Jude Children's Research Hospital investigators. The findings identify possible new targets for...

2011-08-09 07:19:10

(Ivanhoe Newswire) "“ Scientists have completed a map of genetic mutations occurring in the second-most common form of brain cancer, oligodendroglioma. The findings appear to reveal the biological cause of the tumors. Oligodendroglioma accounts for up to 20 percent of brain cancers and more commonly occur in younger people and 30 to 45. To create the map, the scientists sequenced protein-coding genes in seven oligodendroglioma tissue samples, and focused attention on recurring mutations...

2011-08-05 12:08:45

Findings reveal cause of the tumors Johns Hopkins Kimmel Cancer Center scientists have completed a comprehensive map of genetic mutations occurring in the second-most common form of brain cancer, oligodendroglioma. The findings, reported in the Aug. 4 issue of Science, also appear to reveal the biological cause of the tumors, they say. To create the map, the scientists sequenced protein-coding genes in seven oligodendroglioma tissue samples, and focused attention on recurring mutations in two...